Database

Startups

Main Industry
Health Care
Main Product/Service
The brand "惠生大藥局" under 惠生醫藥國際股份有限公司 not only provides prescription dispensing services but has also introduced international-standard health management. Through strategic partnerships with the Japan Institute of Preventive Medicine and Changhua Christian Hospital, it utilizes testing technology, health reports, diet, and exercise to provide tailored health consultations and remote care.
The content above was translated by Ai
Founded Year
2021
Unified Business No.
90686586
Status
Active
Number of Employees
0
Total Paid-in Capital
15,440,000 (NT$)
Location of Company
Taiwan , Taichung City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups. Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed. Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
About the Company
惠生醫藥國際股份有限公司 takes health and longevity as its core philosophy, encompassing interventions at the physical, mental, spiritual, and social levels. It aims to build appropriate environmental facilities and transportation for the elderly of today and those who will emerge over the next decade, enabling them to enjoy high-quality health services and a safe community environment, so that every senior citizen can enjoy a comfortable and peaceful life in their later years.


The content above was translated by Ai
more ↓

Similar Companies

SLINGX CORP.

1. "CardioRenix Matrix AI Smart Care Operating System": Creating the world's first clinical biochemical signal infrastructure layer integrating "decentralized real-time diagnosis, continuous AI risk prediction, and health insurance payment mechanisms," transforming medical records into digital smart assets.
2. "Matrix929™ Real-Time Microfluidic Analyzer": The exclusive patented N-DNA™ technology successfully overcomes the "Debye Screening Wall" that has blocked the industry for 30 years. With just a single drop of whole blood at your fingertip, you can generate central laboratory-level data within 15 minutes with sensitivity reaching fM (fimolar) levels, surpassing traditional optical inspection by 1,000 times. A single cartridge can quantitatively detect eight key CKM biomarkers including hs-cTnI, NT-proBNP, and HbA1c, quantifying micro-deterioration trends in organs.
3. "EvoRisk™ AI Prediction Engine and L1 Growth Memory Layer": This is the system's digital brain. The L1 growth memory layer uses MySQL (factual memory: biochemical indicators and prescriptions), Redis (state memory: real-time follow-up progress), and Graphiti (contextual memory: causal relationship maps of complaints and indicators) to transform static medical records into dynamic medical memory. The system self-optimizes through continuous learning mechanisms, predicting major cardiovascular adverse events (MACE) within 12 months with an accuracy of up to 0.90 AUC, advancing the intervention window by 5-10 years.
4. "Dr. AI Health Companion Assistant App": Integrates localized semantic mapping (TW-RAG), automatically de-hallucinating elderly Taiwanese slang names (such as "kidney guai"), and accurately maps them into SNOMED CT (code 709044004 chronic kidney disease) international standard clinical codes. When linked to Apple Watch, if acute warning signs such as HRV/HR anomalies are detected, the UI will be force-taken within 10 seconds to trigger an emergency alert status machine and immediately notify the medical team.
回頁面最頂端